Literature DB >> 2190673

The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent.

R C Jackson1, J S Sebolt, J L Shillis, W R Leopold.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190673     DOI: 10.3109/07357909009017545

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  8 in total

1.  Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Joel M Reid; Mary J Kuffel; Matthew M Ames; Bernd W Scheithauer; Julie E Hammack; George Pipoly; Steven A Kuross
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

Review 2.  Current status of pyrazoloacridine as an anticancer agent.

Authors:  A A Adjei
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.

Authors:  J Vuky; J McCaffrey; M Ginsberg; T Mariani; D F Bajorin; G J Bosl; R J Motzer
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

4.  A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.

Authors:  Alex A Adjei; Joel M Reid; Charles Erlichman; Jeff A Sloan; Henry C Pitot; Steven R Alberts; Richard M Goldberg; Lorelei J Hanson; Stacie Ruben; Scott A Boemer; Pamela Atherton; Matthew M Ames; Scott H Kaufmann
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.

Authors:  Bhuvaneswari Ramaswamy; Ewa Mrozek; John Philip Kuebler; Tanios Bekaii-Saab; Eric H Kraut
Journal:  Invest New Drugs       Date:  2009-10-21       Impact factor: 3.850

6.  Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.

Authors:  M M Zalupski; A F Shields; P A Philip; M Kraut; P LoRusso; L K Heilbrun; V Vaitkevicius
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

7.  Chemotherapy of mammary carcinomas arising in ras transgenic mice.

Authors:  D L Dexter; M Diamond; J Creveling; S F Chen
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

8.  A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.

Authors:  E Claire Dees; Eric K Rowinsky; Dennis A Noe; Seamus O'Reilly; Alex A Adjei; Kathy Elza-Brown; Ross C Donehower
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.